Victor Shengkan Jin, Ph.D. founded Mito Biopharma in 2012 based on his research in modulating mitochondria function and autophagy. The company, structured as a spin-out start-up company from Rutgers University, also obtained an exclusive world-wide license to its technology under an established license agreement with Rutgers University for all potential therapeutic and diagnostic applications. In addition, the company entered into a R&D collaboration agreement with Rutgers University to further evolve the technology on a broader basis and to establish a strong intellectual property foundation. The R&D agreement is currently ongoing.
In parallel, Dr. Jin obtained the financial support of a primary anchor investor, Mega Hill Investment, LTD, to enable critical research activities and the initial recruitment and implementation of key corporate staff. To date, Mega Hill continues as the major investor and shareholder.